Incyte (INCY) Scheduled to Post Quarterly Earnings on Tuesday

Incyte (NASDAQ:INCY) is set to post its quarterly earnings results before the market opens on Tuesday, October 29th. Analysts expect Incyte to post earnings of $1.19 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($2.60). The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Incyte had a return on equity of 0.75% and a net margin of 2.52%. Incyte’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same period last year, the firm posted $0.77 earnings per share. On average, analysts expect Incyte to post $1 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Incyte Price Performance

Incyte stock opened at $65.07 on Monday. The stock has a market cap of $12.53 billion, a P/E ratio of 180.75, a price-to-earnings-growth ratio of 5.31 and a beta of 0.73. The company has a fifty day simple moving average of $65.15 and a 200-day simple moving average of $61.30. Incyte has a 12-month low of $50.27 and a 12-month high of $70.36. The company has a current ratio of 1.92, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01.

Insider Transactions at Incyte

In other news, insider Thomas Tray sold 572 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $62.94, for a total transaction of $36,001.68. Following the transaction, the insider now directly owns 24,825 shares in the company, valued at $1,562,485.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Thomas Tray sold 572 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $62.94, for a total transaction of $36,001.68. Following the transaction, the insider now directly owns 24,825 shares in the company, valued at $1,562,485.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jonathan Elliott Dickinson sold 8,450 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $62.36, for a total transaction of $526,942.00. Following the transaction, the executive vice president now owns 36,390 shares in the company, valued at $2,269,280.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 17.60% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Guggenheim lifted their price objective on shares of Incyte from $86.00 to $92.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Cantor Fitzgerald reissued a “neutral” rating on shares of Incyte in a research report on Monday, September 16th. William Blair reissued an “outperform” rating on shares of Incyte in a research report on Monday, September 9th. JPMorgan Chase & Co. boosted their price target on shares of Incyte from $61.00 to $65.00 and gave the company a “neutral” rating in a research report on Wednesday, October 23rd. Finally, JMP Securities reissued a “market perform” rating on shares of Incyte in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Incyte currently has an average rating of “Hold” and a consensus price target of $73.42.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.